Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 22, 2006 Brian Lawler	Implant Approval Gives Allergan a Lift The return of silicone breast implants continues. Shares of Allergan, best known for its Botox wrinkle treatment, were up nearly 8% on the news.
The Motley Fool May 27, 2009 Brian Orelli	A Wrinkle in the Botox Plan The FDA turns down Allergan's label expansion, but it wasn't all bad news.
The Motley Fool June 5, 2008 Brian Lawler	Allergan Lashes Out The pharmaceutical announces a new drug that could promote eyelash growth.
The Motley Fool December 16, 2005 Stephen D. Simpson	A Romantic Rectangle in Health Care First Medicis wants Inamed, then Allergan wants Inamed. Now Mentor wants Medicis. Strange days in health care, to be sure. Investors, take note.
BusinessWeek December 25, 2006 Palmeri & Weintraub	Silicone Goes Subtle Allergan's campaign relies on friendly persuasion.
The Motley Fool May 19, 2006 Jim Mueller	Foolish Forecast: Mentor's Uncertain Results Factors outside of the cosmetic surgery products maker's control are leading to short-term uncertainty. Investors, take note.
Chemistry World January 25, 2013 Andrew Turley	Allergan buys MAP for $958m Allergan, best known as the company behind Botox (onabotulinumtoxin A) injections, has agreed to buy US drug maker MAP Pharmaceuticals for $958 million
The Motley Fool August 4, 2004 Roger Nusbaum	Inamed Waiting for Good News This multifaceted medical device company, which sells breast implants, awaits an FDA decision. The biggest risk is the stock getting caught in a general health sector downturn.
The Motley Fool August 8, 2006 Stephen D. Simpson	Waiting on Fine Figures From Mentor Flush with cash, medical aesthetics specialist Mentor needs to reinvest in growth. This is a fine company that rarely trades cheap -- investors, take note.
The Motley Fool September 12, 2008 Brian Lawler	A New Wrinkle for an Old Drug Allergan's muscle relaxant Botox performs well in two studies testing its ability to prevent migraine headaches.
Chemistry World June 24, 2015 Matthew Gunther	Allergan to buy out Kythera Biopharma for $2.1bn The pharma firm Allergan will acquire Kythera Biopharmaceuticals in a $2.1 billion deal.
BusinessWeek October 13, 2003 Arlene Weintraub	He Bet on Botox -- And Won David Pyott transformed sleepy Allergan. Where is he taking its blockbuster drug?
The Motley Fool December 15, 2003 Alyce Lomax	No Wrinkles for Medicis Medicis Pharmaceuticals announced that the FDA has approved its injectable wrinkle-filling gel, Restylane. Allergan's Botox has found a new competitor in the fountain-of-youth market.
The Motley Fool September 20, 2007 Brian Lawler	Allergan's Overactive Acquisition Specialty pharma Allergan announced yesterday that it is acquiring privately held Esprit Pharma for $370 million in an all-cash transaction. Investors, take note.
BusinessWeek March 25, 2010 Elizabeth Lopatto	And Now, Gastric Surgery for Kids Allergan wants to market its Lap-Band implants for younger obese patients, but some doctors are balking
CRM February 2003 David Myron	Support Gets a Face-Lift Allergan was able to automate the routing of 80 percent of all inbound, Web-generated emails, based on the business rules the company put in place.
The Motley Fool January 23, 2004 Jean Graham	Keeping Abreast of Implants Inamed's race with Mentor for first rights to the silicone breast implant market hits a snag.
The Motley Fool March 2, 2011 Susmita Chatterjee	How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others?
BusinessWeek April 25, 2005 Catherine Arnst	Breast Implants: Science vs. Emotion Lobbying and politics are having a huge effect on the debate over whether to allow silicone breast implants back on the market.
Chemistry World April 29, 2014 Phillip Broadwith	Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time.
The Motley Fool April 14, 2005 Rich Duprey	Mentor the Winner on Implants An FDA panel gives Mentor the right to market breast implants after denying Inamed's application. On the news, Inamed's stock fell by more than 3%, and then nearly 7% in early morning trading.
The Motley Fool January 15, 2009 Robert Steyer	Medicis Tries to Save Face The wrinkle-removal drugmaker hopes it can smooth out a tough economy.
The Motley Fool May 6, 2009 Robert Steyer	Getting Ahead by Getting Rid of Wrinkles Medicis gets the FDA OK for an anti-wrinkle product as the market for Botox and other cosmetic skin drugs sags.
AskMen.com Dustin Driver	Male Plastic Surgery If you're thinking about surgical body modifications, keep reading. The following procedures can be performed in a matter of hours by a skilled plastic surgeon.
CIO December 14, 2010 Kim S. Nash	How Botox Battles Compliance Wrinkles A BPM overhaul saved the day after legal issues complicated compliance at Botox-maker Allergan.
BusinessWeek October 11, 2004 Gene G. Marcial	Clear Vistas at Advanced Medical Optics This manufacturer of eye surgery products isn't a household name, but its stock hit a 52-week high of 43 in late June, up from 17 in November. And a recent slide is no sign of a downturn, says one investment analyst.
The Motley Fool October 7, 2009 Jim Mueller	Daily Walk of Shame: Money-Hungry Drugmakers If Allergan wins its suit against the government, consumers will really be in trouble.
The Motley Fool February 9, 2006 Stephen D. Simpson	Alcon Makes Traders Cry Disappointing guidance lets some of the air out of the valuation, but not enough.
Chemistry World June 10, 2008 James Mitchell Crow	A Drug for Longer Lashes? US drugmaker Allergan, the California-based company that makes antiwrinkle treatment Botox, has developed a new cosmetic drug that makes eyelashes grow longer, thicker and darker.
The Motley Fool April 6, 2011 Brian Orelli	Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire.
The Motley Fool January 2, 2004 Dave Marino-Nachison	Medicis: Skin Is In The drug maker has a strong balance sheet and a commitment to product development.
The Motley Fool December 29, 2008 Brian Orelli	Thicker Lashes, Fatter Wallets The Food and Drug Administration approves Allergan's Latisse, a treatment for sparse eyelashes.
Chemistry World July 28, 2014 Andy Extance	Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover.
Chemistry World July 29, 2015 Katrina Megget	Allergan steps away from generics with sale to Teva In something of a surprise move, Allergan has committed to selling its generics business to Israeli generics giant Teva for $40.5 billion, despite having no prior plans to sell.
The Motley Fool May 14, 2007 Mike Havrilla	Investors Tire of Inspire Pharmaceuticals Shares are down about 10% recently, despite approval for AzaSite.
Chemistry World November 24, 2014 Andy Extance	Actavis rescues Allergan with $66 billion deal The acrimonious seven-month battle over the future of US biotech Allergan looks to be over, after the Botox-maker accepted a 'white knight' takeover bid from Actavis.
The Motley Fool March 4, 2010 Brian Orelli	A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan.
The Motley Fool April 19, 2005 Stephen D. Simpson	Do The Eyes Have It for Bausch & Lomb? New product launches and extensions coupled with improving margins should boost results. Investors, take note.